Vasopeptides pp 155-166 | Cite as

Inhibition by Sulfhydryl Reagents of the Effects of Bradykinin, Arachidonic Acid and “Slow Reacting Substance C”

  • B. B. Vargaftig
  • N. Dao Hai
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 21)


Acidic antiinflammatory agents inhibit bronchoconstriction due to bradykinin (1), arachidonic acid (AA) (2), and Slow Reacting Substance C (SRS-C) (3), and suppress completely the hypotension due to SRS-C in the rabbit and in the dog (3, 4) as well as the secondary hypotension bradykinin evokes in the rabbit (5) and in the guinea-pig (6). It has been proposed that a new mediator, called “Rabbit Aorta Contracting Substance” (RCS), which is released by anaphylaxis, bradykinin, Slow Reacting Substance A (SRS-A) (7), SRS-C and AA (8), is involved in those effects of the mentioned agonists which are blocked by nonsteroidal antiinflammatory agents (7, 8); RCS release from the guinea-pig lung is blocked by phenylbutazone — like drugs.


Arachidonic Acid Sodium Cromoglycate Rabbit Aorta Propranolol Hydrochloride Sulfhydryl Reagent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Collier, H.O.J., and Shorley, F.G., Brit. J. Pharmacol., 15, 601, 1960.PubMedGoogle Scholar
  2. 2.
    Berry, P.A., Ph. Thesis, London, 1966.Google Scholar
  3. 3.
    Vargaftig, B.B., Miranda, E.P., and Lacoume, B., Nature, 222, 883, 1969.PubMedCrossRefGoogle Scholar
  4. 4.
    Vargaftig, B.B., and DAO HAI, N., J. Pharmacol. (Paris), 3, 287, 1971.Google Scholar
  5. 5.
    Vargaftig, B.B., Experientia, 22, 182, 1966.PubMedCrossRefGoogle Scholar
  6. 6.
    Collier, H.O.J., Dinnen, L.C., Perkins, A.C., and piper, P.J., arch. exp. path. pharmak., 269, 159, 1968.Google Scholar
  7. 7.
    PIPER, P.J., and VANE, J.R., Nature, 223, 29, 1969.PubMedCrossRefGoogle Scholar
  8. 8.
    VARGAFTIG, B.B., and DAO HAI, N., Pharmacology, 6, 99, 1971.PubMedCrossRefGoogle Scholar
  9. 9.
    FERREIRA, S.H., and ROCHA e SILVA, M., Biochem. Pharmac., 11, 1123, 1962.CrossRefGoogle Scholar
  10. 10.
    ERDOS, E.G., and WOHLER, J.R., Biochem. Pharmac., 12, 1193, 1963.CrossRefGoogle Scholar
  11. 11.
    KONZETT, H., and ROSSLER, R., Arch. exp. Path.,Pharmak., 195, 71, 1940.CrossRefGoogle Scholar
  12. 12.
    COLLIER, H.O.J., in Hypotensive Peptides, Springer Verlag, 305, 1966.CrossRefGoogle Scholar
  13. 13.
    VARGAFTIG, B.B., and COIRON, M., J. Pharmacol. (Paris), 2, 155, 1971.Google Scholar
  14. 14.
    VOGT, W., J. Physiol. (Loud.), 136, 131, 1957.Google Scholar
  15. 15.
    ANGGARD, E., and SAMUELSSON, B., J. Biol. Chem., 210, 3518, 1965.Google Scholar
  16. 16.
    VANE, J.R., Nature, 231, 235, 1971.Google Scholar
  17. 17.
    LANDS, W., LEE, R., and SMITH, W., in Prostaglandins, Ann. N. Y. Acad. Sci., 107, 1970.Google Scholar
  18. 18.
    WILLIS, A.L., Pharmacol. Res. Comm., 2, 297, 1970.CrossRefGoogle Scholar
  19. 19.
    SONDERGAARD, J., and GREAVES, M.W., J. Pathol., 101, 93, 1970.PubMedCrossRefGoogle Scholar
  20. 20.
    KUNZE, J., and VOGT, W., in Prostaglandins, Ann. N.Y. Acad. Sci., 123, 1971.Google Scholar
  21. 21.
    VARGAFTIG, B.B., and DAO HAI, N., Experientia, 1972.Google Scholar
  22. 22.
    VARGAFTIG, B.B., and DAO HAI, N., Europ. J. Pharmacol., 1972.Google Scholar

Copyright information

© Plenum Press, New York 1972

Authors and Affiliations

  • B. B. Vargaftig
    • 1
  • N. Dao Hai
    • 1
  1. 1.Organon R & D, S. A. R. L.60-Eragny-sur-EpteFrance

Personalised recommendations